BR112016004355A2 - constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo - Google Patents
constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmoInfo
- Publication number
- BR112016004355A2 BR112016004355A2 BR112016004355A BR112016004355A BR112016004355A2 BR 112016004355 A2 BR112016004355 A2 BR 112016004355A2 BR 112016004355 A BR112016004355 A BR 112016004355A BR 112016004355 A BR112016004355 A BR 112016004355A BR 112016004355 A2 BR112016004355 A2 BR 112016004355A2
- Authority
- BR
- Brazil
- Prior art keywords
- fab
- present
- poly
- effector fusion
- preparation
- Prior art date
Links
- 239000012636 effector Substances 0.000 abstract 5
- 102000037865 fusion proteins Human genes 0.000 abstract 4
- 108020001507 fusion proteins Proteins 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 238000001727 in vivo Methods 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000001322 periplasm Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130104112 | 2013-08-30 | ||
| PCT/KR2014/008106 WO2015030539A1 (en) | 2013-08-30 | 2014-08-29 | An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016004355A2 true BR112016004355A2 (pt) | 2017-10-17 |
Family
ID=52586989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016004355A BR112016004355A2 (pt) | 2013-08-30 | 2014-08-29 | constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9879077B2 (enExample) |
| EP (2) | EP3632930A1 (enExample) |
| JP (2) | JP6422977B2 (enExample) |
| KR (2) | KR101576561B1 (enExample) |
| CN (1) | CN105899532B (enExample) |
| AU (1) | AU2014312456B2 (enExample) |
| BR (1) | BR112016004355A2 (enExample) |
| CA (1) | CA2922618C (enExample) |
| DK (1) | DK3039038T3 (enExample) |
| ES (1) | ES2866848T3 (enExample) |
| MX (1) | MX371328B (enExample) |
| PH (1) | PH12016500403A1 (enExample) |
| PL (1) | PL3039038T3 (enExample) |
| RU (1) | RU2661087C2 (enExample) |
| UA (1) | UA117493C2 (enExample) |
| WO (1) | WO2015030539A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108623691B (zh) * | 2017-03-17 | 2020-05-15 | 北京比洋生物技术有限公司 | IgG样长效免疫融合蛋白及其应用 |
| KR20210022004A (ko) * | 2018-06-18 | 2021-03-02 | 안위타 바이오사이언시스, 인코포레이티드 | 항-메소텔린 작제물 및 이의 용도 |
| EP3930687A4 (en) | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| KR102485892B1 (ko) * | 2020-04-09 | 2023-01-09 | 주식회사 에이프릴바이오 | 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도 |
| KR20220044057A (ko) * | 2020-09-29 | 2022-04-06 | 주식회사 에이프릴바이오 | 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도 |
| CN119343367A (zh) * | 2022-06-15 | 2025-01-21 | Ucb生物制药有限责任公司 | 卵泡抑素融合蛋白 |
| KR20240048577A (ko) * | 2022-10-04 | 2024-04-16 | 주식회사 에이프릴바이오 | 난포자극 호르몬 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도 |
| CN118393137B (zh) * | 2024-07-01 | 2024-08-20 | 广东赛尔生物科技有限公司 | 一种肠道保护菌的检测试剂盒及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW517061B (en) * | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| DE60305919T2 (de) * | 2002-06-28 | 2007-01-18 | Domantis Limited, Cambridge | Dual-specifische liganden mit erhöhter halbwertszeit |
| GB0315450D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| BRPI0511755A (pt) * | 2004-06-01 | 2008-01-02 | Domantis Ltd | composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização |
| CN101031588A (zh) * | 2004-06-01 | 2007-09-05 | 多曼蒂斯有限公司 | 药物组合物，融合物和结合物 |
| BRPI0514259A (pt) * | 2004-08-11 | 2008-06-03 | Trubion Pharmaceuticals Inc | proteìna de fusão de domìnio de ligação |
| KR20070073886A (ko) * | 2004-10-05 | 2007-07-10 | 제넨테크, 인크. | 독성이 감소된 치료제 |
| RU2007119989A (ru) * | 2004-12-02 | 2009-01-10 | Домантис Лимитед (Gb) | Композиции, слитые конструкции и конъюгаты plad домена |
| CA2596925C (en) * | 2005-02-08 | 2017-07-04 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Method for improving expression level and stability of antibody |
| WO2008151319A2 (en) * | 2007-06-08 | 2008-12-11 | Dow Global Technologies Inc. | Expression of soluble antibody fragment by truncation of ch1 domain |
| CA2700714C (en) * | 2007-09-26 | 2018-09-11 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| KR20110008086A (ko) * | 2008-04-11 | 2011-01-25 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
| CN102164965B (zh) * | 2008-09-26 | 2016-03-30 | Ucb医药有限公司 | 生物产品 |
| EA026508B1 (ru) * | 2008-12-05 | 2017-04-28 | Глэксо Груп Лимитед | Единичный вариабельный домен иммуноглобулина и выделенный устойчивый к протеазе полипептид, связывающие сывороточный альбумин человека |
| EP2461831B1 (en) * | 2009-08-06 | 2018-11-21 | Novo Nordisk Health Care AG | Growth hormones with prolonged in-vivo efficacy |
| GB201005063D0 (en) * | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| CA2774552A1 (en) * | 2009-09-30 | 2011-04-07 | Glaxo Group Limited | Drug fusions and conjugates with extended half life |
| CN107903325B (zh) * | 2011-05-16 | 2021-10-29 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
| BR112014011304B1 (pt) * | 2011-11-11 | 2022-03-03 | UCB Biopharma SRL | Anticorpos de ligação com albumina e fragmentos de ligação dos mesmos, proteína de fusão de anticorpo bi-específico, polinucleotídeo, célula hospedeira, processo de produção de anticorpo ou fragamento do mesmo, formulação farmacêutica e uso |
-
2014
- 2014-08-29 JP JP2016538860A patent/JP6422977B2/ja active Active
- 2014-08-29 AU AU2014312456A patent/AU2014312456B2/en active Active
- 2014-08-29 EP EP19192902.5A patent/EP3632930A1/en not_active Withdrawn
- 2014-08-29 CA CA2922618A patent/CA2922618C/en active Active
- 2014-08-29 ES ES14839630T patent/ES2866848T3/es active Active
- 2014-08-29 CN CN201480056265.1A patent/CN105899532B/zh active Active
- 2014-08-29 DK DK14839630.2T patent/DK3039038T3/da active
- 2014-08-29 MX MX2016002539A patent/MX371328B/es active IP Right Grant
- 2014-08-29 UA UAA201601685A patent/UA117493C2/uk unknown
- 2014-08-29 EP EP14839630.2A patent/EP3039038B1/en active Active
- 2014-08-29 BR BR112016004355A patent/BR112016004355A2/pt not_active Application Discontinuation
- 2014-08-29 PL PL14839630T patent/PL3039038T3/pl unknown
- 2014-08-29 RU RU2016105586A patent/RU2661087C2/ru active
- 2014-08-29 WO PCT/KR2014/008106 patent/WO2015030539A1/en not_active Ceased
- 2014-09-01 KR KR1020140115673A patent/KR101576561B1/ko active Active
-
2015
- 2015-09-25 KR KR1020150136164A patent/KR20150118565A/ko not_active Ceased
-
2016
- 2016-02-29 US US15/056,299 patent/US9879077B2/en active Active
- 2016-02-29 PH PH12016500403A patent/PH12016500403A1/en unknown
-
2017
- 2017-09-27 US US15/717,528 patent/US10618953B2/en active Active
-
2018
- 2018-06-01 JP JP2018106308A patent/JP6800180B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2661087C2 (ru) | 2018-07-11 |
| CA2922618A1 (en) | 2015-03-05 |
| EP3039038A4 (en) | 2017-07-05 |
| AU2014312456A8 (en) | 2016-03-17 |
| KR101576561B1 (ko) | 2015-12-10 |
| KR20150118565A (ko) | 2015-10-22 |
| US20160376350A1 (en) | 2016-12-29 |
| JP6422977B2 (ja) | 2018-11-14 |
| JP6800180B2 (ja) | 2020-12-16 |
| US9879077B2 (en) | 2018-01-30 |
| UA117493C2 (uk) | 2018-08-10 |
| PL3039038T3 (pl) | 2021-04-19 |
| KR20150026997A (ko) | 2015-03-11 |
| EP3039038B1 (en) | 2020-11-25 |
| PH12016500403A1 (en) | 2016-05-16 |
| JP2018172391A (ja) | 2018-11-08 |
| AU2014312456A1 (en) | 2016-03-03 |
| US20180030127A1 (en) | 2018-02-01 |
| US10618953B2 (en) | 2020-04-14 |
| ES2866848T3 (es) | 2021-10-19 |
| AU2014312456B2 (en) | 2017-07-06 |
| CA2922618C (en) | 2020-04-28 |
| MX2016002539A (es) | 2016-10-13 |
| CN105899532A (zh) | 2016-08-24 |
| EP3039038A1 (en) | 2016-07-06 |
| JP2016528922A (ja) | 2016-09-23 |
| EP3632930A1 (en) | 2020-04-08 |
| RU2016105586A (ru) | 2017-10-04 |
| HK1223107A1 (zh) | 2017-07-21 |
| WO2015030539A1 (en) | 2015-03-05 |
| MX371328B (es) | 2020-01-27 |
| DK3039038T3 (da) | 2021-02-08 |
| CN105899532B (zh) | 2021-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016004355A2 (pt) | constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo | |
| CL2018000226A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| EA201391753A1 (ru) | Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| MX386884B (es) | Pares de unión para producción de péptidos | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| EA201591700A1 (ru) | Гибридные белки апелина и их применение | |
| MX2016008355A (es) | Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos. | |
| EP3889185A3 (en) | Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage | |
| PE20142167A1 (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
| BR112014001573B8 (pt) | Molécula fv ao antígeno multivalente | |
| WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
| PE20190733A1 (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y metodos de uso | |
| WO2014144542A3 (en) | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same | |
| BR112019008351A2 (pt) | imunoglobulinas e usos das mesmas | |
| CA2866232A1 (en) | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition | |
| HRP20170905T1 (hr) | Antikancerogeni fuzijski protein | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
| AR111764A1 (es) | Proteína de unión a antígeno, anticuerpo que la comprende, cadena peptídica comprendida en el anticuerpo y composiciones relacionadas | |
| PE20081687A1 (es) | Proteina de fusion | |
| EA202090084A1 (ru) | Новый терапевтический ферментный слитый белок и его применение | |
| BR112015018035A2 (pt) | anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno | |
| PE20190633A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023013900-3 PROTOCOLO 870230060709 EM 11/07/2023 16:35. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |